TL;DR
A review in Nutrients examined research on ergothioneine, an antioxidant found in mushrooms and other foods, and its possible effects on brain health. Some observational and early trial findings are encouraging, but they do not show that eating mushrooms or taking ergothioneine prevents dementia or other neurodegenerative diseases.
A review published in the journal Nutrients examines whether ergothioneine, a naturally occurring compound found in mushrooms and other foods, could help protect the aging brain. Researchers at the University of Rzeszow in Poland report promising findings from observational studies and laboratory and animal experiments, but say the evidence does not establish that ergothioneine—or eating more mushrooms—prevents neurodegenerative disease in people.
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The researchers reviewed studies on ergothioneine, often shortened to ET, and its potential effects on cognition, inflammation and the survival of nerve cells. ET is a thiol antioxidant. Antioxidants have been studied because oxidative stress accompanies neurodegenerative diseases and may contribute to them, though its role is not settled. The review describes ET as a possible preventive or therapeutic compound, not an established treatment.
Several observational studies found that people with lower ET levels in their blood tended to have worse cognitive outcomes or certain diagnoses. One study of 470 people who did not have cognitive impairment at the start linked lower ET levels with faster declines across measures including memory, attention, language and locomotor function. Other studies reported lower levels among people with mild cognitive impairment or Parkinson’s disease, and linked lower levels in people with mild cognitive impairment to a greater likelihood of later Alzheimer’s disease.
Those studies show associations, not cause and effect. Low ET could contribute to brain changes, but it could also reflect other factors, including increased antioxidant use during oxidative stress. The review also notes conflicting evidence: one study associated higher serum ET with increased Alzheimer’s risk. The authors describe protective results in cells and animal models, alongside small human trials with limited outcomes. Some experiments used doses higher than typical dietary intake or concentrations that may not be achievable in people.
What the Findings Mean for Diet
The research helps explain why scientists are investigating ET as a possible marker or contributor to brain health. If future studies establish a causal role, the compound could become relevant to prevention research or treatment development. For now, the findings do not support a specific dietary prescription or a claim that mushrooms protect against dementia.
That distinction matters to readers because observational links can be misleading when presented as proof that a food prevents disease. The review is a synthesis of existing research, not a clinical trial showing that people who eat more mushrooms retain memory longer. Nor does it establish that taking an ET supplement can prevent or treat Alzheimer’s, Parkinson’s or other neurodegenerative conditions. The human evidence described is early and often concerns short-term or subjective outcomes rather than disease prevention.
Products Worth Considering
LG StanbyME 2 Max 32-Inch 4K Portable Smart Touchscreen TV
Bose Lifestyle Ultra Soundbar and Ultra Subwoofer Bundle
LG 55-Inch QNED73B Mini LED 4K Smart TV (2026)
As an affiliate, we earn on qualifying purchases.
From Cell Studies to Human Trials
The review puts ET research against the broader challenge of neurodegenerative disease. These conditions can reduce quality of life and independence for patients and affect caregivers; the report states that there is currently no cure for these diseases. Oxidative stress is one area of investigation, and antioxidant compounds have been proposed as possible protective agents. A previous review suggested that insufficient dietary ET might contribute to neurodegeneration, but the current authors describe that idea as unproven.
In laboratory studies, ET reduced reactive oxygen species and protected some cells from damage. Animal-model research reported reduced behavioral or cognitive deficits in models of Alzheimer’s and Parkinson’s disease. In a Parkinson’s model using the worm Caenorhabditis elegans, ET was associated with protection of dopamine-producing neurons, less alpha-synuclein aggregation and oxidative stress, and longer lifespan. Such findings can guide research, but results in cells and animals do not show that the same effects occur at ordinary dietary exposures in humans.
Human studies cited in the review were limited in length and scope. ET administration for up to 35 days was associated with downward trends in some blood and urine markers of inflammation and oxidative damage, but the changes were not statistically significant. Other trials reported changes in sleep or memory measures. A 12-week trial of mushroom extract tablets reported improved verbal memory, but the extract contained other compounds, so the effect cannot be attributed to ET alone.
“The hypothesis that dietary ET deficiency may contribute to neurodegeneration remains unproven.”
— Researchers at the University of Rzeszow, as summarized in the review
What Human Studies Cannot Yet Show
The review does not establish whether ET itself lowers the risk of neurodegenerative disease, whether low blood levels are a cause or consequence of illness, or how much ET people would need to consume for any effect. It also does not establish that dietary mushroom intake produces the same results as concentrated extracts or doses used in experiments.
Some human findings involved small or short trials and outcomes such as self-reported sleep quality. In one study of people with subjective memory complaints, a higher ET dose temporarily improved a composite memory measure at week four of a 16-week trial. The review does not establish that this temporary change led to lasting benefit. Researchers have proposed that sleep effects might relate to later Parkinson’s onset, but that possibility has not been proven in humans.
Evidence Needed Before Dietary Claims
The next step is stronger human research that can distinguish ET’s effects from other dietary, health and lifestyle factors. Longer and larger trials would need to test defined doses, track clinically meaningful cognitive outcomes over time, and clarify whether results from supplements apply to foods such as mushrooms. Studies would also need to address the conflicting observational findings and determine how blood ET levels relate to intake and disease progression.
Until such evidence is available, the review supports continued investigation rather than a claim that eating more mushrooms will protect the brain. The researchers’ synthesis identifies a plausible research direction, while leaving the central question—whether ET can prevent or slow neurodegenerative disease in people—unanswered.
Key Questions
Does eating more mushrooms prevent dementia?
The review does not show that mushroom consumption prevents dementia. It examines research on ergothioneine, which is found in mushrooms and other foods, but the evidence is not sufficient to establish a preventive effect in people.
What is ergothioneine?
Ergothioneine is a naturally occurring thiol antioxidant found in mushrooms and some other foods. Researchers are studying its possible effects on oxidative stress, inflammation and brain cells.
Do lower ergothioneine levels cause cognitive decline?
That is not known. Some observational studies linked lower blood levels with worse cognition or neurodegenerative disease, but they cannot show whether low ET contributes to those outcomes or results from other changes.
Have ergothioneine supplements been shown to protect the brain?
No. The review describes early human trials with limited outcomes, as well as cell and animal research. It does not establish that supplements prevent or treat Alzheimer’s, Parkinson’s or other neurodegenerative diseases.
Source: news-medical.net
